BIDU-SW
09888
NTES-S
09999
BOSS ZHIPIN-W
02076
JD-SW
09618
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|
Cash flow from operating activities | |||||
Earning before tax | -15.56%-59.58M | -70.68%-89.8M | ---51.56M | -108.03%-52.61M | ---25.29M |
Profit adjustment | |||||
Interest (income) - adjustment | 18.80%-1.27M | 18.64%-2.31M | ---1.57M | -45.94%-2.84M | ---1.95M |
Investment loss (gain) | 68.58%-647K | 64.05%-2.66M | ---2.06M | -4.91%-7.39M | ---7.05M |
Attributable subsidiary (profit) loss | ---- | ---- | ---- | 92.96%-5K | ---71K |
Impairment and provisions: | -58.78%5.47M | 102.76%21.07M | --13.26M | 362.94%10.39M | --2.25M |
-Impairmen of inventory (reversal) | -36.23%6.53M | 97.90%17.07M | --10.24M | 59.06%8.63M | --5.42M |
-Impairment of trade receivables (reversal) | -137.21%-1.1M | 299.28%3.91M | --2.94M | 128.70%979K | ---3.41M |
-Other impairments and provisions | -61.11%28K | -88.20%93K | --72K | 238.20%788K | --233K |
Revaluation surplus: | 29.17%-1.6M | -740.25%-3.36M | ---2.26M | 76.40%-400K | ---1.7M |
-Other fair value changes | 29.17%-1.6M | -740.25%-3.36M | ---2.26M | 76.40%-400K | ---1.7M |
Asset sale loss (gain): | -97.95%4K | 114.70%599K | --195K | 66.07%279K | --168K |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---- | --163K |
-Loss (gain) on sale of property, machinery and equipment | --4K | 20,300.00%404K | ---- | -140.00%-2K | --5K |
-Loss (gain) from selling other assets | ---- | -30.60%195K | --195K | --281K | ---- |
Depreciation and amortization: | 14.80%16.8M | 46.23%33.33M | --14.63M | 172.84%22.79M | --8.35M |
-Amortization of intangible assets | 31.88%484K | 20.89%758K | --367K | 426.89%627K | --119K |
Financial expense | -50.25%702K | -3.60%1.96M | --1.41M | 164.67%2.03M | --767K |
Special items | 133.79%13.67M | 70.63%21.46M | --5.85M | 1,078.91%12.58M | ---1.29M |
Operating profit before the change of operating capital | -19.74%-26.47M | -29.85%-19.71M | ---22.11M | 41.18%-15.18M | ---25.8M |
Change of operating capital | |||||
Inventory (increase) decrease | 37.66%-23.14M | 64.76%-29.32M | ---37.12M | -152.32%-83.2M | ---32.97M |
Accounts receivable (increase)decrease | 7.35%9.66M | 79.66%-5.08M | --9M | -575.78%-24.98M | ---3.7M |
Accounts payable increase (decrease) | 54.14%-6.25M | -174.05%-19.5M | ---13.64M | 627.61%26.33M | ---4.99M |
prepayments (increase)decrease | 107.86%278K | -209.62%-10.55M | ---3.54M | -314.20%-3.41M | --1.59M |
Special items for working capital changes | -0.29%-10.9M | -130.23%-35.08M | ---10.87M | -121.10%-15.24M | --72.24M |
Cash from business operations | 27.40%-56.83M | -3.10%-119.25M | ---78.27M | -1,916.62%-115.66M | --6.37M |
Other taxs | 63.10%-13.59M | -4,440.14%-38.46M | ---36.82M | ---847K | ---- |
Net cash from operations | 38.82%-70.41M | -35.35%-157.7M | ---115.09M | -1,929.92%-116.51M | --6.37M |
Cash flow from investment activities | |||||
Interest received - investment | -18.80%1.27M | -18.64%2.31M | --1.57M | 45.94%2.84M | --1.95M |
Sale of fixed assets | 144.25%1.63M | 275.22%424K | --669K | -70.88%113K | --388K |
Purchase of fixed assets | -22.24%-7.64M | 47.48%-11.31M | ---6.25M | 49.33%-21.53M | ---42.48M |
Purchase of intangible assets | ---1.21M | 97.48%-52K | ---- | 2.78%-2.06M | ---2.12M |
Sale of subsidiaries | ---- | ---- | ---- | ---- | ---251K |
Recovery of cash from investments | -89.41%32.4M | -46.60%392.55M | --306.04M | -10.97%735.11M | --825.66M |
Cash on investment | 99.43%-1.6M | 42.60%-370.25M | ---282.52M | 38.86%-645M | ---1.06B |
Other items in the investment business | ---- | ---71.54M | ---71.54M | ---- | ---- |
Net cash from investment operations | 147.77%24.86M | -183.28%-57.86M | ---52.03M | 125.56%69.48M | ---271.88M |
Net cash before financing | 72.74%-45.56M | -358.34%-215.56M | ---167.12M | 82.29%-47.03M | ---265.51M |
Cash flow from financing activities | |||||
New borrowing | 753.36%69.23M | 167.31%57.79M | --8.11M | 395.39%21.62M | --4.36M |
Refund | ---57.79M | ---21.62M | ---- | ---- | ---27.41M |
Interest paid - financing | 53.40%-541K | 11.83%-1.5M | ---1.16M | -360.43%-1.7M | ---369K |
Absorb investment income | ---- | ---- | ---- | -40.63%183.53M | --309.14M |
Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | 33.50%-4.27M | ---6.42M |
Net cash from financing operations | 137.42%7.82M | -85.49%28.14M | --3.29M | -29.47%193.97M | --275.01M |
Effect of rate | -113.50%-187K | -63.77%626K | --1.39M | 704.20%1.73M | ---286K |
Net Cash | 76.96%-37.74M | -227.55%-187.43M | ---163.83M | 1,446.76%146.94M | --9.5M |
Begining period cash | -62.73%110.96M | 99.72%297.76M | --297.76M | 6.59%149.09M | --139.88M |
Cash at the end | -46.03%73.03M | -62.73%110.96M | --135.32M | 99.72%297.76M | --149.09M |
Cash balance analysis | |||||
Cash and bank balance | -52.88%63.77M | -68.92%92.55M | --135.32M | 130.66%297.76M | --129.09M |
Cash and cash equivalent balance | -52.88%63.77M | -68.92%92.55M | --135.32M | 130.66%297.76M | --129.09M |
Currency Unit | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.